- Home
- CING vs DXR Comparison
CING vs DXR Comparison
Compare CING & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CING | DXR |
|---|---|---|
| Founded | 2012 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 59.0M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | CING | DXR |
|---|---|---|
| Price | $5.21 | $10.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $34.50 | N/A |
| AVG Volume (30 Days) | ★ 133.6K | 8.7K |
| Earning Date | 05-08-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | N/A | $74.79 |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.16 | $8.56 |
| 52 Week High | $11.89 | $14.76 |
Technical Indicators
Market Signals| Indicator | CING | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 56.73 |
| Support Level | $5.08 | $9.26 |
| Resistance Level | $5.54 | $10.99 |
| Average True Range (ATR) | 0.31 | 0.52 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 27.17 | 82.80 |
Price Performance
Historical ComparisonAbout CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.